Press Release: Skeena Resources Limited Announces the Filing of the Prospectus Supplement in Respect of Its Approximately C$125 Million Bought Deal Financing
VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX: SKE, NYSE: SKE) (“Skeena Gold & Silver”, “Skeena” or the “Company”) is pleased to announce that it has filed a prospectus supplement and entered into an underwriting agreement (the “Underwriting Agreement”) with a syndicate of underwriters led by BMO Capital Markets (collectively,…
WINNIPEG, Manitoba, Nov. 20, 2025 (GLOBE NEWSWIRE) -- (TSX: NWC): The North West Company Inc. (the “Company” or “North West”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted notice of the Company’s intention to make a normal course issuer bid (“NCIB”) for a portion of its common voting shares and variable voting shares…
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against StubHub Holdings, Inc. (“StubHub” or the “Company”) (NYSE:STUB). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 12, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) securities between October 22, 2024…
SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 8th Annual Evercore Healthcare Conference, taking place in Miami, including a fireside chat on Wednesday, December 3, 2025, at 1:20 pm ET. The webcast will be available…
Boehringer Ingelheim, a global leader in preventive medicines for livestock, obtained positive opinions by the European Medicines Agency (EMA) recommending the granting of marketing authorisations under exceptional circumstances2 for its avian influenza vaccines VAXXITEK® HVT+IBD+H5 and VAXXINACT® H5. Both vaccines immunize birds against the H5 avian influenza virus, which is currently causing outbreaks across Europe.
